Alcoholism in Britain? There’s a Pill for That

pill

Everything’s coming up binge drinkers!

Britain’s National Institute for Health and Care Excellence (NICE) has approved the use of Nalmefene, a drug that curbs alcohol dependence. NICE serves the English and Welsh National Health Services (NHS) which allows both nations to join Scotland in prescribing the drug.

The Scottish Medicines Consortium (SMC) approved Nalmefene last year to combat the country’s considerably higher rate of alcohol-related deaths, but all three nations require counseling along with the pill.

Got your acronyms down?

NICE expects 35,000 people to receive the Chantix of alcohol dependency in the first year, but only 53 people in Scotland were prescribed the drug since it hit the market.

Chalk it up to denial?

Since a recent study showed that most Americans who think they might be alcoholics are just excessive drinkers, the target demographic for Nalmefene, the drug may soon be Food and Drug Administration (FDA–acronym game strong) approved for more than opioid dependence.

Whether or not this use of the drug crosses the pond, it’s an interesting, albeit pricey, way to deal with a growing problem.

Pop Quiz: Still remember those acronyms?

H/T: The Guardian

 

More content

CultureLifestyle
Amazon Is Shutting Down Its Grocery Stores—And Doubling Down On Delivery And Whole Foods
Amazon is pulling the plug on its Amazon Go and Amazon Fresh physical stores, marking a quiet but telling shift in how the company wants…
,
LifestyleProducts
Where Have All The Vegans Gone? Beyond Meat & Impossible Foods Pivot Outside Of Alt-Meat
“Where have all the vegans gone?” was a question posed to me by a colleague in response to what the market has shown is a…
,
LifestyleProducts
Lucky Charms & Cinnamon Toast Crunch Meet Protein In The Most Unexpected Cereal Collab Yet
Ghost Protein, a lifestyle sports nutrition brand, has launched its latest collaboration with General Mills, this time pumping protein into Lucky Charms and Cinnamon Toast…
,
Burger
We Deliver!

Enter your email address below and we'll deliver our top stories straight to your inbox